Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC3134
Trial ID NCT05477186
Disease COVID-19
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment CV0501
PhasePhase1
Recruitment statusCompleted
TitleA Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Year2022
CountryUnited States|Australia|Philippines
Company sponsorGlaxoSmithKline
Other ID(s)218595
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: CV0501_dose level 3
Administration route intramuscular injection
Dosage CV0501, 12 µg
Age Adult, Older_Adult
References PMID: 36851196
Cohort2: CV0501_dose level 4
Administration route intramuscular injection
Dosage CV0501, 25 μg
Age Adult, Older_Adult
References PMID: 36851196
Cohort3: CV0501_dose level 5
Administration route intramuscular injection
Dosage CV0501, 50 μg
Age Adult, Older_Adult
References PMID: 36851196
Cohort4: CV0501_dose level 6_dose level 7
Administration route intramuscular injection
Dosage CV0501, 75 μg; CV0501, 100 μg
Age Adult, Older_Adult
References PMID: 36851196
Cohort5: CV0501_dose level 7_dose level 8_dose level 9
Administration route intramuscular injection
Dosage CV0501, 100 μg; CV0501, 150 μg; CV0501, 200 μg
Age Adult, Older_Adult
References PMID: 36851196
Cohort6: CV0501_dose level 2
Administration route intramuscular injection
Dosage CV0501, 6 ug
Age Adult, Older_Adult
References PMID: 36851196
Cohort7: CV0501_dose level 1
Administration route intramuscular injection
Dosage CV0501, 3 ug
Age Adult, Older_Adult
References PMID: 36851196

Relationship Graph

Overview of Knowledge Graph